# Real-Data Readiness Audit: Local EODHD 50 Blue-Chip Diagnostic Cohort

Date: 2026-09-20.
Audit Decision: `diagnostic_ready_with_low_caveats`.
Evidence Ceiling: `DIAGNOSTIC_ONLY`.
Survivorship Bias: `true` (static snapshot of 50 liquid large-cap symbols).
Dataset Manifest Reviewed: `false`.
Formal Interpretation Eligible: `false`.

This audit evaluates the local EODHD daily Parquet dataset covering the 50-stock blue-chip cohort plus the `SPY.US` benchmark under the requirements of `.agents/skills/real-data-readiness-audit/SKILL.md` and `AGENTS.md`.

---

## 1. Scope and Authority

- **Dataset**: Local normalized daily Parquet snapshot (`snapshot_20260808T005805Z`) acquired from EODHD.
- **Inventory**: Relative stock coverage inventory (`per_stock_coverage.json`) mapping symbols to Parquet files under `data_dir`.
- **Cohort**: 50 liquid U.S. blue-chip equities (`BLUECHIP_50_COHORT`) spanning all 11 GICS sectors:
  `AAPL.US`, `MSFT.US`, `NVDA.US`, `AMZN.US`, `GOOGL.US`, `META.US`, `BRK-B.US`, `UNH.US`, `JNJ.US`, `JPM.US`,
  `V.US`, `PG.US`, `XOM.US`, `HD.US`, `CVX.US`, `MA.US`, `LLY.US`, `ABBV.US`, `MRK.US`, `PEP.US`,
  `KO.US`, `BAC.US`, `TMO.US`, `WMT.US`, `COST.US`, `CSCO.US`, `MCD.US`, `DIS.US`, `ACN.US`, `ABT.US`,
  `ADBE.US`, `CRM.US`, `LIN.US`, `NKE.US`, `PFE.US`, `CMCSA.US`, `DHR.US`, `TXN.US`, `VZ.US`, `PM.US`,
  `INTC.US`, `AMD.US`, `HON.US`, `WFC.US`, `UPS.US`, `QCOM.US`, `IBM.US`, `CAT.US`, `GE.US`, `AMGN.US`.
- **Benchmark**: `SPY.US` (SPDR S&P 500 ETF Trust).
- **Target Evaluation Window**: 10-year period from 2016-08-08 to 2026-08-07 (2,514 trading days).

---

## 2. Integrity and Schema Verification

| Check | Result | Verification Detail |
|---|---|---|
| **File Resolution** | Pass | All 51 symbols successfully resolved via relative inventory paths under `data_dir` without path escape. |
| **Schema Conformance** | Pass | Required fields present across all files: `date`, `open`, `high`, `low`, `close`, `adjusted_close`, `volume`. |
| **Date Monotonicity** | Pass | Dates are strictly increasing with zero duplicate rows per symbol. |
| **Calendar Alignment** | Pass | Dates normalized to calendar-day midnight (`freq=None`). Union alignment across all 51 assets yields exactly 2,514 trading dates matching `SPY.US`. |
| **Missing Data (PIT-009)** | Pass | Zero missing values across all 51 symbols for the 10-year window (2,514 observations × 51 assets = 128,214 cells per field, 0 nulls). |
| **Price Bounds** | Pass | Strictly positive finite floats. Close range: `[$5.49, $3731.41]`. |
| **Volume Bounds** | Pass | Non-negative finite floats. Min volume: `67,200.0`. |
| **Type Integrity** | Pass | No boolean dtypes or boolean-disguised object values. |

---

## 3. Research Safety and Causal Execution

- **Lookahead Prevention**:
  - Signals are generated at time $t$ using data strictly through date $t$.
  - Execution occurs at the next observed row $t+1$ under the accepted `after_close_signal_next_observed_close_v1` timing convention (`signal_lag_periods=1`).
  - Factor combinations use causal expanding-window walk-forward IC weights (`walk_forward_ic_weighted_composite`) adhering to M01.
  - Turnover smoothing references are frozen at decision time adhering to M02.
  - Exposure is strictly gross-normalized with signed position caps adhering to M03 and M06.
- **Non-Execution Safeguards**:
  - All research scripts run in simulation mode only.
  - No brokerage connections, order placement, or live trading capabilities exist.

---

## 4. Caveats and Limitations

1. **Survivorship Bias**: The cohort is a static snapshot of liquid large-cap blue chips as of August 2026. Companies that delisted, went bankrupt, or were removed from the S&P 500 during the 2016–2026 window are excluded. This introduces positive survivorship bias.
2. **Diagnostic Scope**: Results generated from this cohort are strictly `DIAGNOSTIC_ONLY`. They serve to validate multi-factor model pipelines on empirical market data and do not represent formal investment performance or live trading readiness.
3. **Formal Readiness Deferred**: Point-in-time constituent lineage tracking, immutable experiment trial ledgering (charter Stage 4), and formal promotion gates remain deferred to subsequent Milestone 4 phases.

---

## 5. Audit Decision

**`diagnostic_ready_with_low_caveats`**

The 50-stock blue-chip cohort and SPY benchmark from the local EODHD daily Parquet dataset meet all data integrity, date alignment, and schema requirements. The dataset is approved for diagnostic multi-factor research runs under `DIAGNOSTIC_ONLY` status with explicit survivorship caveats.
